Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,278 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

NCT01644643
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer

NCT00137436
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Prednisone, SU011248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
24
States / cities
Harvey, Illinois • Tinley Park, Illinois • Hobart, Indiana + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Oct 30, 2026, 2:52 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Muscle Malonyl Coa Biomarker Assay Development

NCT01003444
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Muscle biopsy
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers

NCT00312364
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetes Complications
Interventions
MRE0094
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Montgomery, Alabama • Bullhead City, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

NCT00006399
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil, Estrogen, Progesterone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
45 Years to 85 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 15, 2009 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

NCT01465802
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Dacomitinib, Doxycycline, Probiotic, Alclometasone cream
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
79
States / cities
Duarte, California • Fullerton, California • Irvine, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

NCT00987337
View directory record Official record
Conditions
Hepatitis, Hepatitis C
Interventions
Filibuvir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
30
States / cities
Anaheim, California • Coronado, California • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

NCT00853385
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo, Biologic TNFi
Drug · Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
38
States / cities
Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Pregabalin in Fibromyalgia

NCT00151489
View directory record Official record
Conditions
Fibromyalgia
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
109
States / cities
Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 30, 2026, 2:52 AM EDT
Terminated Phase 3 Interventional Results available

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

NCT00676650
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Prednisone, sunitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Decatur, Alabama • Huntsville, Alabama • Anaheim, California + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Different Tablet Formulations Of Bosutinib

NCT00934674
View directory record Official record
Conditions
Healthy
Interventions
SKI-606 (Bosutinib)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT00969813
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

NCT06897202
View directory record Official record
Conditions
Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
Interventions
MET097 Injection, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
29
States / cities
Bessemer, Alabama • Chula Vista, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Voriconazole in Obese Subjects

NCT01030653
View directory record Official record
Conditions
Healthy
Interventions
Voriconazole low dose, Voriconazole high dose
Drug
Lead sponsor
Manjunath Prakash Pai
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 30, 2026, 2:52 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

NCT00823979
View directory record Official record
Conditions
HIV-1
Interventions
UK-453,061 Dose 1, UK-453,061 Dose 2, Etravirine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
21
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 30, 2026, 2:52 AM EDT
Terminated Phase 3 Interventional

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

NCT00391196
View directory record Official record
Conditions
Obesity
Interventions
Placebo, CP-945,598, CP-945,598 Treatment B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653
View directory record Official record
Conditions
Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Apixaban, No systemic anticoagulant prophylaxis
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

NCT01005472
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
sunitinib malate, temozolomide
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

NCT02070939
View directory record Official record
Conditions
Healthy
Interventions
PF-06260414, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bifeprunox in Bipolar Depression

NCT00134459
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Bifeprunox, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
40
States / cities
Birmingham, Alabama • Beverly Hills, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 30, 2026, 2:52 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
PF-06821497, Placebo, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
39
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 2:52 AM EDT
Completed No phase listed Observational

Assessment of Suicidality in Epilepsy - Rating Tools

NCT01085461
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
The Epilepsy Study Consortium
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Knee

NCT00733902
View directory record Official record
Conditions
Arthritis, Osteoarthritis
Interventions
tanezumab, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
82
States / cities
Phoenix, Arizona • Danbury, Connecticut • Stamford, Connecticut + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 30, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.

NCT07575945
View directory record Official record
Conditions
Healthy Participant
Interventions
PF-08642534, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 2:52 AM EDT